(Total Views: 644)
Posted On: 06/11/2022 2:38:58 AM
Post# of 155002
An interesting read on NAFLD/NASH.
What negative factors for NASH progression mentioned in the article does leronlimab downregulate? Almost all of them - NLRP3, IL-1b, TNF-a, IL-6, IL-18, NLRP1, ASC, caspase-1, GSDMD, NF-kB, ATP, ROS.
They propose a variety of NLRP3 inhibitors as possibilities for NAFLD/NASH but none of them have approval. Leronlimab has a much broader reach than NLRP3 for NASH. An example ROS can induce NLRP3 activation, but leronlimab can downregulate ROS and it's other negative effects besides NLRP3.
Quote:
The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment
https://www.frontiersin.org/articles/10.3389/...80496/full
What negative factors for NASH progression mentioned in the article does leronlimab downregulate? Almost all of them - NLRP3, IL-1b, TNF-a, IL-6, IL-18, NLRP1, ASC, caspase-1, GSDMD, NF-kB, ATP, ROS.
They propose a variety of NLRP3 inhibitors as possibilities for NAFLD/NASH but none of them have approval. Leronlimab has a much broader reach than NLRP3 for NASH. An example ROS can induce NLRP3 activation, but leronlimab can downregulate ROS and it's other negative effects besides NLRP3.
(10)
(0)
